Impel NeuroPharma, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Impel NeuroPharma, Inc. | IMPL - NASDAQ |
$14.00-$16.00 | $15.00 | $15.31 | 5.33 million | 4/23/2021 |
| Cowen, Guggenheim | ||||||
Co-Manager(s): Wedbush PacGrow
| ||||||
| Health Care | ||||||
Filing(s): | ||||||
Impel NeuroPharma, Inc. Quote & Chart - Click for current quote - IMPL
IPO Boutique aggregates information on public companies and private companies, such as "IMPL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Impel NeuroPharma, Inc. (adapted from Impel NeuroPharma, Inc. prospectus):
They are a late-stage pharmaceutical company focused on utilizing our proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system, or CNS.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a late-stage pharmaceutical company focused on utilizing our proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system, or CNS.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "IMPL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.